{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:07:15Z","timestamp":1740460035869,"version":"3.37.3"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"125","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2012,6,19]]},"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>A growing body of published evidence exists on the risk factors for disease progression in pulmonary arterial hypertension (PAH). The Scientific Steering Committee for the Study of Risk in PAH was established to bring together leading clinical and statistical experts in PAH and risk modelling, for the purpose of advancing the understanding of the risk of development and progression of PAH. Herein, we discuss the impact of this information on three key areas: 1) clinical decision-making; 2) policy and reimbursement; and 3) future trials and research.<\/jats:p>","DOI":"10.1183\/09059180.00003712","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T20:45:31Z","timestamp":1346532331000},"page":"234-238","source":"Crossref","is-referenced-by-count":14,"title":["The study of risk in pulmonary arterial hypertension"],"prefix":"10.1183","volume":"21","author":[{"given":"Lewis J.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kymes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2012,8,31]]},"reference":[{"key":"2024102403001152000_21.125.234.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"2024102403001152000_21.125.234.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898122"},{"key":"2024102403001152000_21.125.234.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2024102403001152000_21.125.234.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010"},{"key":"2024102403001152000_21.125.234.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0676"},{"key":"2024102403001152000_21.125.234.6","first-page":"21","article-title":"Current era survival of pulmonary arterial hypertension (PAH) patients: comparison between clinical sub-groups","volume":"31","author":"Palazzini","year":"2010","journal-title":"Eur Heart J"},{"key":"2024102403001152000_21.125.234.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.30541"},{"key":"2024102403001152000_21.125.234.8","first-page":"A5898","article-title":"Short term response to sildenafil therapy for pulmonary arterial hypertension is associated with long term outcome","volume":"183","author":"Layton","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403001152000_21.125.234.9","first-page":"A4806","article-title":"International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL): aims, design, methods, and baseline characteristics of patients","volume":"181","author":"Pittrow","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403001152000_21.125.234.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-2-216"},{"key":"2024102403001152000_21.125.234.11","first-page":"A4792","article-title":"Relationship between baseline pulmonary capillary wedge pressure and response to sildenafil treatment in pulmonary arterial hypertension","volume":"185","author":"Champion","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403001152000_21.125.234.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00072911"},{"key":"2024102403001152000_21.125.234.13","first-page":"A3828","article-title":"Validation of the French pulmonary hypertension network equation to estimate survival: a REVEAL analysis","volume":"185","author":"McGoon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403001152000_21.125.234.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092311"},{"key":"2024102403001152000_21.125.234.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139009"},{"key":"2024102403001152000_21.125.234.16","unstructured":"Prospective longitudinal study of patients with idiopathic pulmonary arterial hypertension, family ortakinganorectics(EFORT). NCT01185730. www.clinicaltrials.gov\/ct2\/show\/NCT01185730 Date last accessed: May 2012. Date last updated: July 1, 2012."},{"key":"2024102403001152000_21.125.234.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2024102403001152000_21.125.234.18","unstructured":"A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension(PAH)(AMBITION). NCT01178073. www.clinicaltrials.gov\/ct2\/show\/NCT01178073 Date last accessed: May 2012. Date last updated: December 8, 2011."},{"key":"2024102403001152000_21.125.234.19","unstructured":"Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension(PAH)(COMPASS-2study). NCT00303459. www.clinicaltrials.gov\/ct2\/show\/NCT00303459 Date last accessed: May 2012. Date last updated: February 17, 2012."},{"key":"2024102403001152000_21.125.234.20","unstructured":"Assess the efficacy and safety of sildenafil when added to bosentan in the treatment of pulmonary arterial hypertension. NCT00323297. www.clinicaltrials.gov\/ct2\/show\/NCT00323297 Date last accessed: May 2012. Date last updated: June 15, 2012."},{"key":"2024102403001152000_21.125.234.21","first-page":"A5910","article-title":"Upfront triple combination therapy of i.v. epoprostenol with oral bosentan and sildenafil in idiopathic and heritable pulmonary arterial hypertension","volume":"183","author":"Sitbon","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403001152000_21.125.234.22","doi-asserted-by":"crossref","unstructured":"Drummond MF Sculpher MJ Torrance GW . eds. Methods for the Economic Evaluation of Health Care Programmes. 3rd Edn. Oxford, Oxford University Press, 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"2024102403001152000_21.125.234.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13490","article-title":"Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation","volume":"13","author":"Chen","year":"2009","journal-title":"Health Technol Assess"},{"key":"2024102403001152000_21.125.234.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-3513-4"},{"key":"2024102403001152000_21.125.234.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1119980"},{"key":"2024102403001152000_21.125.234.26","first-page":"A3833","article-title":"Development of a new patient-reported outcome measure to estimate functional capacity in patients with pulmonary arterial hypertension","volume":"185","author":"Chen","year":"2012","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09059180.00003712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:55:34Z","timestamp":1740372934000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09059180.00003712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,31]]},"references-count":26,"journal-issue":{"issue":"125","published-online":{"date-parts":[[2012,8,31]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1183\/09059180.00003712"],"URL":"https:\/\/doi.org\/10.1183\/09059180.00003712","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"type":"print","value":"0905-9180"},{"type":"electronic","value":"1600-0617"}],"subject":[],"published":{"date-parts":[[2012,8,31]]}}}